미래형 T세포를 이용한 면역치료가 암 치료 영역을 석권한 지 오래지만, 다른 첨단 치료법을 개발하여 암 면역치료의 영역을 넓혀야 한다는 요구가 있습니다. 하지만 그럼에도 불구하고 감마 델타 T세포, 알파 베타 T세포 등 다른 T세포 수용체의 발견으로 이어지고 있습니다. 이후 감마 델타 T세포를 기반으로 한 면역치료제가 발견되면서 감마 델타 T세포를 기반으로 한 면역치료제 개발이 바이러스 감염, 자가면역, 염증을 포함한 다른 질환과 함께 암에 대한 혁신적인 치료법을 제공하는 데 일조할 수 있다는 것이 더욱 현실적으로 다가오고 있습니다.
감마 델타 T세포 기반 면역요법의 세계 임상 라인은 30개 품목(2024년 6월 기준)으로 구성되어 있으며, 그 중 일부 품목은 전임상 단계에 있으며, 이 분야의 연구개발과 기술 발전의 대부분은 미국과 중국 지역에서 진행 중입니다. 하지만 암 및 기타 질병을 치료하는 약품은 아직 상업 시장에 침투하지 못했습니다. 그러나 한 가지 약물이 승인되면 다른 감마 델타 T세포 기반 면역요법이 시장에 출시되어 수백만 달러 규모의 시장이 될 가능성이 있습니다.
감마 델타 T세포 기반 면역요법 시장의 성장을 촉진하는 전략적 원동력 중 하나는 전임상 및 임상시험의 증가입니다. 지난 10년간 세계 감마 델타 T세포 기반 면역요법 시장은 몇 가지 새롭고 혁신적이며 진보적인 경쟁업체들의 개발을 촉진했습니다. 예를 들어, 미국의 임상 단계에 있는 생명공학 기업 Acepodia Biotech는 PD-L1을 발현하는 고형 종양과 EGFR을 발현하는 종양을 치료하기 위해 ACE1708과 ACE2016이라는 두 가지 경쟁 약물을 개발했습니다.
이 보고서는 세계 암 감마 델타 T세포 치료 시장을 조사했으며, 시장 개요와 함께 암 치료에서 감마 델타 T세포의 역할, 지역별 동향, 임상시험 동향, 시장 진입 기업의 경쟁 동향 등을 조사하여 전해드립니다.
Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030 Report Conclusions:
After vicennium of futuristic T cells entrenched immunotherapy dominating the treatment landscape of cancer arena, there is a prerequisite to branch out cancer immunotherapy realm by developing other state-of-the-art therapies. But in spite of that, this led to discovery of other T cells receptors, such as gamma delta T cells, alpha-beta T cell and others. Consecutively, finding of gamma delta T cells based immunotherapy (also recognized as Yδ T cells), it was further pragmatic that developing gamma delta T cells based immunotherapies will aid to offer a innovatory treatment for cancer along with other disorders, including viral infections, autoimmune and inflammation.
With respect to KuicK Research statistics, the global clinical conduit of gamma delta T cells based immunotherapy comprises of 30 drugs (as of June 2024), several of which are in preclinical stage as well as majority of research and development along with technological advancement in in this sector is ongoing in the US and China region. Albeit, no drug has penetrated into the commercial market to treat cancer or other ailments; however, as soon as one drug will get approved will aid to launch other gamma delta T cells based immunotherapy into market and clenches potential to become a multimillionaire market in imminent.
One of the strategic prime movers that bestow to bourgeon the growth of gamma delta T cells based immunotherapy market is the rise in preclinical and clinical studies. Over the preceding decennium, the sphere of global gamma delta T cells based immunotherapy market has witnessed the development of several novel, innovative as well as advanced competitors. For instance, a clinical-stage biotechnology company in US, Acepodia Biotech has developed 2 contenders, ACE1708 as well as ACE2016 to treat solid tumor expressing PD-L1 accompanied with EGFR expressing tumors.
Coupled with this, the presences of various stakeholders in conjugation with investors from giant pharma companies accompanied with biotech companies, such as Bristol Myers Squibb, TC Biopharm, PersonGen BioTherapeutics, In8bio, Kiromic BioPharma, Immatics, Legend Biotech, Innate Pharma, Ever Supreme Bio Technology, Editas Medicine, CytoMed Therapeutics, Acepodia Biotech and other have bestowed to transform the treatment paradigm by developing up-to-the-minute gamma delta T cells based immunotherapy worldwide. Amid all these companies, PersonGen BioTherapeutics is the frontrunner in this segment as the company is developing 5 allogeneic UCAR- Yδ1 T cell therapy for the treatment of autoimmune, T cell malignancies and other solid tumors. The presences of giant pharmaceuticals aid to conduct multitudinous clinical trials in gamma delta T cells based immunotherapy space.
Just as importantly, an inclining market trend towards developing avant-garde global gamma delta T cells based immunotherapy, such as developing gamma-delta gene editing based immunotherapy, is gaining spotlight amid healthcare professionals. For instance, a biotech company based in Germany, Immatics has collaborated with Bristol Myers Squibb and Editas Medicine in order To syndicate gamma-delta T cell based adoptive cell therapies in addition to gene editing for the treatment of cancer.
Until now, no gamma delta T cells based immunotherapies has been approved in global market; nevertheless, it can be anticipated that a handful of gamma delta T cells therapies will be launched into the market in approaching 5 to 7 years due to the fact that many gamma delta T cells based immunotherapies have received FDA designations which aid to accelerate the approval process. For instance, ADI-001 has gained utmost breakthrough as it has received FDA fast track designation for the potential treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), in 2022, and relapsed/refractory class III or class IV lupus nephritis in June 2024. Overall, aforementioned illustrates clearly forecasts that the future of gamma delta T cells based immunotherapies will be propitious.